Skip to main content
Retour
TARS logo

Tarsus Pharmaceuticals, Inc.

Qualité des données : 100%
TARS
NASDAQ Healthcare Biotechnology
64,13 €
▼ 0,38 € (-0,59%)
Cap. Boursière : 2,73B
Fourchette du Jour
63,54 € 67,31 €
Fourchette 52 Semaines
38,51 € 85,25 €
Volume
808 345
Moyenne 50J / 200J
69,58 € / 62,35 €
Clôture Précédente
64,51 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -41,1 0,4
P/B 8,0 2,9
ROE % -23,4 3,8
Net Margin % -14,7 3,9
Rev Growth 5Y % 67,7 10,0
D/E 0,3 0,2

Objectif de Cours des Analystes

Hold
89,00 € +38.8%
Low: 68,00 € High: 100,00 €
BPA Prévisionnel
-0,63 €
CA Est.
690 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 9,19 €
8,89 € – 9,67 €
1,3 B 2
FY2029 6,99 €
6,76 € – 7,35 €
1,2 B 2
FY2028 5,08 €
3,10 € – 6,73 €
1,1 B 4

Points Clés

Revenue grew 67,73% annually over 5 years — strong growth
Debt/Equity of 0,27 — conservative balance sheet
Negative free cash flow of -22,31M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 78,98%
Capital efficient — spends only 2,18% of revenue on capex

Croissance

Revenue Growth (5Y)
67,73%
Revenue (1Y)146,71%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-23,39%
ROIC-12,18%
Net Margin-14,72%
Op. Margin-15,72%

Sécurité

Debt / Equity
0,27
Current Ratio3,85
Interest Coverage-7,94

Valorisation

P/E Ratio
-41,09
P/B Ratio7,95
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 146,71% Revenue Growth (3Y) 408,63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 67,73% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 451,36M Net Income (TTM) -66,42M
ROE -23,39% ROA -11,81%
Gross Margin 93,20% Operating Margin -15,72%
Net Margin -14,72% Free Cash Flow (TTM) -22,31M
ROIC -12,18% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,27 Current Ratio 3,85
Interest Coverage -7,94 Dividend Yield 0,00%
Valuation
P/E Ratio -41,09 P/B Ratio 7,95
P/S Ratio 6,05 PEG Ratio 1,07
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,73B Enterprise Value 2,64B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 451,36M 182,95M 17,45M 25,82M 57,03M
Net Income -66,42M -115,55M -135,89M -62,09M -13,83M
EPS (Diluted) -1,59 -3,07 -4,62 -2,52 -0,67
Gross Profit 420,68M 170,13M 15,85M 24,86M 54,95M
Operating Income -70,97M -120,57M -143,16M -62,71M -12,16M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 562,16M 376,99M 265,49M 227,86M 178,91M
Total Liabilities 218,73M 152,46M 68,50M 34,96M 12,18M
Shareholders' Equity 343,43M 224,53M 196,99M 192,90M 166,73M
Total Debt 93,64M 72,45M 30,22M 20,21M 1,89M
Cash & Equivalents 183,64M 94,82M 224,95M 71,66M 171,33M
Current Assets 522,78M 356,71M 256,13M 225,38M 175,95M
Current Liabilities 135,70M 80,61M 36,94M 15,43M 11,48M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#7 of 146
76

Activité Récente

Entré Full Throttle
Mar 24, 2026